{ "schemaVersion": 2, "eyebrow": "Gastroenterology", "title": "Anticoagulation After Gastrointestinal Bleeding", "summary": "After gastrointestinal bleeding, restart anticoagulation once hemostasis is secured in most patients, because interruption lowers rebleeding exposure but increases thromboembolism and death. Timing depends on lesion control, bleeding trajectory, anticoagulant pharmacology, and the indication-specific thrombotic risk.", "seoDescription": "Practical timing and selection framework for restarting warfarin or DOACs after gastrointestinal bleeding once endoscopic hemostasis is achieved.", "clinicalQuestion": "When and how should oral anticoagulation be resumed after gastrointestinal bleeding?", "specialty": "Gastroenterology", "audience": "U.S. physicians and medical trainees", "tags": [ "gastrointestinal bleeding", "anticoagulation resumption", "DOAC restart", "warfarin restart", "endoscopic hemostasis", "thromboembolism" ], "keyTakeaways": [ "Do not make anticoagulant resumption automatic or indefinite discontinuation routine: after bleeding cessation, restarting anticoagulation is generally associated with lower thromboembolism and mortality despite some increase in rebleeding risk. [3][9][21][24]", "Achieve endoscopic, radiologic, or surgical hemostasis as indicated; acute GI hemostatic intervention can be performed at therapeutic anticoagulation levels when necessary. [3]", "For high thrombotic-risk patients, consider early DOAC resumption after hemostasis because anticoagulant effect returns within hours; heparin bridging is generally unnecessary for DOACs. [4][5][22][23]", "For warfarin, the restart decision must account for delayed re-anticoagulation and vitamin K reversal; recommendations range from restarting after day 3 in high-risk patients to 7-15 days for most patients. [5][6]", "Reassess the continuing indication, concomitant antiplatelet exposure, renal function, liver disease, recurrent-bleeding history, and lesion-directed prevention before selecting the restart regimen. [4][13][20][23]" ], "sections": [ { "id": "stabilize-and-establish-hemostasis", "eyebrow": "First decision", "heading": "Do not restart until the bleeding source and hemostatic endpoint are defined", "intro": "The restart clock begins after effective bleeding control, not at presentation.", "paragraphs": [ "Hold the oral anticoagulant during active clinically significant GI bleeding, determine the last dose and agent, and pursue definitive hemostasis with endoscopic therapy or radiologic intervention when indicated. Acute endoscopic or radiologic intervention can be performed effectively in anticoagulated patients; the immediate objective is control of the GI source rather than waiting for complete drug clearance. [3]", "Document the lesion and adequacy of hemostasis before choosing a restart date. A treated focal lesion with sustained cessation of bleeding supports earlier re-exposure than an untreated, recurrent, malignant, variceal, or otherwise unresolved source. Prior GI bleeding is an important predictor of recurrent bleeding during DOAC treatment, so a prior event should trigger review of the source and modifiable coexposures rather than empiric permanent anticoagulant cessation. [13]", "If warfarin excess requires reversal, recognize that vitamin K reduces subsequent responsiveness to warfarin and can leave the patient without therapeutic anticoagulation for a prolonged interval. When rapid anticoagulation is subsequently required, heparin may be preferable during re-establishment of anticoagulation, but this decision should be individualized to the thrombotic indication and post-hemostasis bleeding risk. [2]" ], "bullets": [ "Before restart, record: anticoagulant indication, agent, last dose, renal and hepatic status, endoscopic or radiologic findings, hemostatic intervention, transfusion requirement, and concomitant aspirin, P2Y12 inhibitor, or NSAID exposure. [3][13][20]", "Use CHA2DS2-VASc and HAS-BLED as structured inputs in atrial fibrillation, but do not let either score substitute for assessing whether the GI lesion has been definitively controlled. [4]", "For significant GI bleeding requiring endoscopic or radiologic intervention, coordinate the restart decision with gastroenterology and the clinician managing the anticoagulant indication. [3][23]" ], "subsections": [], "table": { "caption": "Hemostatic features that determine whether anticoagulant restart can be considered. [3][13]", "columns": [ "Finding", "Interpretation", "Next action" ], "rows": [ [ "Bleeding cessation after endoscopic or radiologic source control", "A defined hemostatic endpoint permits individualized restart planning. [3]", "Estimate thrombotic risk and select a restart window by agent and lesion stability. [3][4]" ], [ "Persistent bleeding, uncertain source, or no durable hemostasis", "Re-anticoagulation may expose the patient to uncontrolled recurrent hemorrhage. [3]", "Continue diagnostic and hemostatic management before selecting a restart date. [3]" ], [ "Previous GI bleed or ongoing antiplatelet exposure", "Recurrent-bleeding risk is increased and requires medication and source review. [13][20]", "Remove nonessential bleeding-promoting drugs and address lesion-specific prevention before restart. [13][20]" ] ] } }, { "id": "balance-thrombosis-and-rebleeding", "eyebrow": "Risk tradeoff", "heading": "Restart anticoagulation in most patients with an ongoing indication", "intro": "The central choice is timing, not whether an anticoagulant-associated GI bleed automatically ends anticoagulation.", "paragraphs": [ "Observational studies and meta-analyses consistently find a net clinical benefit from restarting anticoagulation after GI bleeding: thromboembolism and death decrease, while recurrent bleeding risk increases. In atrial fibrillation, resumption of oral anticoagulation after a first GI bleed reduced thromboembolism but increased major bleeding without a statistically significant increase in recurrent GI bleeding in a Danish nationwide study. [3][9][21][24]", "Treat thrombotic risk as highest when the anticoagulant indication remains compelling and interruption is likely to have immediate consequence. In atrial fibrillation, use CHA2DS2-VASc to structure embolic-risk assessment; in all patients, account for the indication, prior thromboembolism, and whether antiplatelet therapy is also necessary. High cardiovascular risk favors avoiding unnecessary delay once hemostasis is achieved. [4]", "Separate anticoagulant management from antiplatelet management. In patients taking aspirin for established cardiovascular disease who had actively bleeding peptic ulcers treated endoscopically, immediate aspirin resumption produced lower 8-week all-cause mortality than placebo (1.3% versus 12.9%), although 30-day rebleeding was numerically approximately twice as frequent. This result supports early review with cardiology when aspirin interruption is being considered, particularly when the cardiovascular indication is secondary prevention. [5][6]" ], "bullets": [ "Favor earlier restart after stable hemostasis when thrombotic risk is high and the source has been treated. [4][5]", "Favor delay when the source remains uncorrected, bleeding has not durably ceased, or a repeat hemostatic procedure is likely. [3]", "Avoid adding antiplatelet therapy to anticoagulation unless its indication is clear; combined VKA-antiplatelet regimens have higher GI bleeding risk than either exposure alone. [9]", "Do not use a prior GI bleed alone as a reason to permanently discontinue oral anticoagulation when the original thrombotic indication persists. [24]" ], "subsections": [], "table": { "caption": "Factors that shift the restart decision after GI bleeding. [3][4][5][9]", "columns": [ "Factor", "Favors earlier resumption", "Favors later resumption or reassessment" ], "rows": [ [ "Hemostasis", "Definitive endoscopic or radiologic control with sustained bleeding cessation. [3]", "Persistent bleeding, uncertain source, or incomplete control. [3]" ], [ "Thrombotic indication", "High cardiovascular or thromboembolic risk. [4][5]", "Low or no continuing indication for anticoagulation. [4]" ], [ "Anticoagulant pharmacology", "DOAC effect returns within hours, allowing prompt restoration without bridging. [4][5]", "Warfarin reversal with vitamin K may delay restoration of therapeutic anticoagulation. [2][4]" ], [ "Concurrent antithrombotic therapy", "A time-sensitive cardiovascular indication may support early aspirin resumption after hemostasis. [5][6]", "Nonessential combined antiplatelet-anticoagulant treatment increases bleeding exposure. [9]" ] ] } }, { "id": "timing-by-anticoagulant", "eyebrow": "Timing", "heading": "Choose the restart window by drug pharmacology and thrombotic risk", "intro": "No single interval fits warfarin and all DOAC-treated patients after GI bleeding.", "paragraphs": [ "For warfarin, timing recommendations vary with thrombotic risk and the completeness of hemostasis. The APAGE-APSDE guideline recommends early resumption after day 3 for patients at high thromboembolic risk because early rebleeding decreases considerably after the first 3 days. The guideline also notes ESGE guidance that restarting warfarin between 7 and 15 days appears safe and effective for most patients. [5][6]", "For DOACs, restart after hemostasis can generally occur earlier than with warfarin because drug effect dissipates in approximately 1-2 days after stopping and returns within hours of re-dosing. For high cardiovascular-risk patients, one consensus recommends DOAC resumption within 1-2 days once bleeding is controlled, while recognizing that rapid restoration of anticoagulation can increase rebleeding risk. [4]", "Do not bridge a DOAC interruption with heparin solely to accelerate anticoagulant effect. DOACs have short half-lives and rapid onset, and guidelines state that bridging is unnecessary; perioperative evidence further associates bridging with increased bleeding without reduction in thromboembolism. [5][22][23]", "The evidence base for exact restart timing is limited and heterogeneous. In warfarin-treated patients after GI bleeding, restarting after 7 days rather than after 30 days was associated with lower death and thromboembolism without increased GI bleeding. Use this directional evidence to avoid prolonged interruption when hemostasis is secure, rather than treating day 7 as a universal threshold. [3][11]" ], "bullets": [ "Warfarin, high thrombotic risk: consider restart after day 3 once hemostasis is durable; integrate the delayed return to therapeutic anticoagulation after vitamin K reversal. [5][6][2]", "Warfarin, most patients: a 7-15-day restart interval has been described as safe and effective, subject to lesion control and patient-level thrombotic risk. [5][6]", "DOAC, high thrombotic risk: consider resumption within 1-2 days after controlled bleeding, recognizing rapid onset and rebleeding tradeoff. [4]", "DOAC, any restart: do not use routine heparin bridging. [5][22][23]" ], "subsections": [ { "heading": "When not to extrapolate GI timing", "paragraphs": [ "Do not apply GI-bleed timing to intracranial hemorrhage. Earlier DOAC resumption carries greater concern after intracranial hemorrhage than after GI bleeding, and one cited American Stroke Association recommendation specifies waiting at least 4 weeks after spontaneous intracerebral hemorrhage. [7][10]" ], "bullets": [] } ], "table": { "caption": "Practical restart framework after controlled GI bleeding. [2][4][5][6][11][23]", "columns": [ "Clinical situation", "Timing approach", "Operational point" ], "rows": [ [ "Warfarin with high thromboembolic risk", "Consider restart after day 3 when hemostasis is secure. [5][6]", "Account for delayed re-anticoagulation, particularly after vitamin K reversal. [2][5]" ], [ "Warfarin in most patients after GI bleeding", "Individualize within approximately 7-15 days after the bleeding event. [5][6]", "Avoid prolonged interruption when the anticoagulant indication persists; restart after 7 versus 30 days was associated with lower death and thromboembolism. [11]" ], [ "DOAC with high cardiovascular risk", "Consider resumption within 1-2 days after bleeding control. [4]", "The anticoagulant effect returns within hours; reassess for recurrent bleeding after re-dosing. [4][5]" ], [ "DOAC restarted after hemostasis", "Use the prescribed DOAC regimen without heparin bridging. [5][23]", "Bridging is not needed because DOAC onset is rapid and can increase bleeding risk. [23]" ] ] } }, { "id": "select-and-monitor-restart-regimen", "eyebrow": "Implementation", "heading": "Reduce recurrent bleeding risk before and after resumption", "intro": "Restart should include a medication reconciliation and surveillance plan, not only a date.", "paragraphs": [ "Before restarting, reassess whether the original agent remains appropriate. In DOAC-eligible patients, agent selection should be matched to patient factors, including prior GI bleeding, chronic kidney disease, liver disease, older age, and concurrent antiplatelet therapy. Renal-function monitoring and evidence-based dose adjustment are specifically emphasized in chronic kidney disease. [20][24]", "Identify co-medications that make recurrent bleeding more likely. Risk factors supporting proton-pump inhibitor use include a history of GI bleeding or peptic ulcer disease, Helicobacter pylori infection, cirrhosis, dyspepsia, advanced age, excessive alcohol use, antiplatelet treatment, NSAID use, and corticosteroid exposure. [20]", "At the restart visit or discharge transition, document the intended agent, dose, first dose date, aspirin or P2Y12 plan, renal-function follow-up, and symptoms that require urgent reassessment. For warfarin, restart requires systematic INR testing, tracking, follow-up, and dose adjustment; vitamin K exposure may alter subsequent dose response. [2][17]" ], "bullets": [ "For DOAC treatment, verify renal function before restart and repeat monitoring more closely in chronic kidney disease because dose selection depends on renal status. [20]", "For warfarin, arrange INR surveillance and coordinated dose management rather than unsupervised resumption. [17]", "Consider a proton-pump inhibitor when GI-risk factors are present, particularly prior GI bleeding or concurrent antiplatelet, NSAID, or corticosteroid exposure. [20]", "Reinvestigate recurrent overt bleeding promptly rather than repeatedly holding and restarting anticoagulation without defining the source. [3][13]" ], "subsections": [], "table": { "caption": "Post-restart monitoring targets and actions. [2][13][17][20]", "columns": [ "Domain", "Action", "What changes management" ], "rows": [ [ "Warfarin effect", "Use systematic INR testing, tracking, and dose adjustment after restart. [17]", "Recent vitamin K can reduce warfarin response and requires careful dose re-establishment. [2]" ], [ "Kidney function", "Monitor renal function more closely in chronic kidney disease and use evidence-based anticoagulant dose adjustment. [20]", "Renal decline may require dose reassessment or a different anticoagulant strategy. [20]" ], [ "Rebleeding prevention", "Review prior GI bleed, ulcer history, H. pylori, NSAID, corticosteroid, alcohol, and antiplatelet exposure; consider a proton-pump inhibitor when risk factors are present. [20]", "Persistent risk factors or recurrent bleeding should prompt modification of co-medications and renewed source evaluation. [13][20]" ], [ "Antithrombotic combinations", "Confirm the indication for every antiplatelet drug. [9]", "Unnecessary VKA-antiplatelet combinations increase GI bleeding risk. [9]" ] ] } }, { "id": "multidisciplinary-exceptions", "eyebrow": "Escalation", "heading": "Use multidisciplinary review for competing high-risk indications", "intro": "Complex restart decisions require alignment between lesion control and the reason anticoagulation cannot be safely withheld.", "paragraphs": [ "Obtain multidisciplinary input when the patient has high cardiovascular risk, ongoing antiplatelet requirements, advanced kidney or liver disease, recurrent bleeding, or an uncertain GI source. A consensus approach recommends involving cardiology, gastroenterology, intensive care when relevant, and the patient after bleeding control; nephrology or hepatology input is appropriate when renal or hepatic dysfunction makes anticoagulant selection or dosing uncertain. [4][23]", "For patients with both anticoagulant and antiplatelet indications, explicitly assign each drug an indication and a restart plan. Aspirin interruption after peptic-ulcer bleeding in secondary cardiovascular prevention can carry substantial mortality consequence, whereas combined antithrombotic treatment increases bleeding risk; this is a reason for coordinated risk adjudication, not a reason to restart all agents simultaneously without review. [5][6][9]", "Escalate urgently for recurrent hemodynamic compromise, recurrent overt bleeding after restart, inability to secure endoscopic control, or a suspected non-GI bleeding syndrome. Anticoagulant-associated intracranial hemorrhage requires neurology and neurosurgical input for reversal, procedural decisions, and restart timing rather than use of the GI framework. [23]" ], "bullets": [ "Gastroenterology: confirm lesion-directed hemostasis and determine whether recurrent endoscopic therapy is likely. [3]", "Cardiology or thrombosis clinician: define the short-term consequence of interruption and necessity of concomitant antiplatelet therapy. [4][5]", "Nephrology or hepatology: clarify anticoagulant choice and dosing when advanced chronic kidney disease or cirrhosis is present. [20][23]" ], "subsections": [], "table": { "caption": "Situations requiring individualized restart planning. [4][5][9][20][23]", "columns": [ "Situation", "Why routine timing is inadequate", "Required next step" ], "rows": [ [ "High cardiovascular risk with recent GI hemostasis", "Early anticoagulation may be important, but rapid DOAC onset can increase rebleeding risk. [4]", "Joint gastroenterology-cardiology decision on first dose timing and antiplatelet plan. [4][5]" ], [ "Chronic kidney disease or cirrhosis", "Drug choice and dose may be uncertain, and renal monitoring affects DOAC management. [20][23]", "Reassess renal and hepatic function before selecting the restart regimen. [20][23]" ], [ "Recurrent GI bleeding", "Prior GI bleeding is a major recurrence risk factor in DOAC-treated patients. [13]", "Reassess source, co-medications, and anticoagulant strategy rather than relying on repeated temporary interruption. [13][20]" ], [ "Concurrent aspirin or P2Y12 inhibitor", "Combination therapy increases bleeding exposure, but interruption may create cardiovascular risk. [5][6][9]", "Confirm the indication for each antithrombotic agent with the prescribing specialty. [4][9]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "[PDF] Cellular, Tissue, and Gene Therapies Advisory Committee ... - FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/183676/download", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 2, "title": "[PDF] COUMADIN® TABLETS (Warfarin Sodium Tablets, USP) Crystalline ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 3, "title": "Endoscopy in patients on antiplatelet or anticoagulant therapy - Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/gutjnl/70/9/1611.full.pdf", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 4, "title": "Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018 | Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/67/10/1757", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 5, "title": "Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines | Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/67/3/405", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 6, "title": "Management of patients on antithrombotic agents", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/gutjnl/67/3/405.full.pdf", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 7, "title": "Spontaneous rectal sheath bleed while on DOAC anticoagulation", "detail": "casereports.bmj.com", "url": "https://casereports.bmj.com/content/bmjcr/16/11/e254313.full.pdf", "authors": "casereports.bmj.com", "host": "casereports.bmj.com" }, { "number": 8, "title": "Spontaneous rectal sheath bleed while on DOAC anticoagulation | BMJ Case Reports", "detail": "casereports.bmj.com", "url": "https://casereports.bmj.com/content/16/11/e254313", "authors": "casereports.bmj.com", "host": "casereports.bmj.com" }, { "number": 9, "title": "Timing of anticoagulation restart after serious bleeding in atrial ...", "detail": "heart.bmj.com", "url": "https://heart.bmj.com/content/112/5/253", "authors": "heart.bmj.com", "host": "heart.bmj.com" }, { "number": 10, "title": "Timing of anticoagulation restart after serious bleeding in atrial fibrillation | Heart", "detail": "heart.bmj.com", "url": "https://heart.bmj.com/content/early/2025/07/16/heartjnl-2024-325343.responses", "authors": "heart.bmj.com", "host": "heart.bmj.com" }, { "number": 11, "title": "Timing of anticoagulation restart after serious bleeding in atrial fibrillation", "detail": "heart.bmj.com", "url": "https://heart.bmj.com/content/early/2025/07/16/heartjnl-2024-325343.full", "authors": "heart.bmj.com", "host": "heart.bmj.com" }, { "number": 12, "title": "Management of Nonvariceal Upper Gastrointestinal Bleeding", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M19-1795", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 13, "title": "Risk of gastrointestinal rebleeding in direct oral anticoagulant-treated population | Postgraduate Medical Journal | Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/pmj/article/101/1202/1361/8196324", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 14, "title": "HAS-BLED and CHA2DS2-VASc Scores as Predictors of Bleeding and Thrombotic Risk After Continuous-Flow Ventricular Assist Device Implantation - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1071916414011907", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 15, "title": "Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0016510798700574", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 16, "title": "Management of Anticoagulation-related Bleeding: A... : Iranian Journal of Cardiovascular Medicine", "detail": "journals.lww.com", "url": "https://journals.lww.com/rcvm/fulltext/2026/01000/management_of_anticoagulation_related_bleeding__a.2.aspx?context=latestarticles", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 17, "title": "Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/0002934388901052", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 18, "title": "Restarting Warfarin vs Direct Oral Anticoagulants After Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1542356520315639", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 19, "title": "associated gastrointestinal bleeding: Framework for decisions about ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15466", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 20, "title": "Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation - Johner - 2026 - European Journal of Clinical Investigation - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/eci.70224", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 21, "title": "Recurrent bleeding and thrombotic events after resumption of oral ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/jth.15476", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 22, "title": "Perioperative Anticoagulation Management - StatPearls - NCBI - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK557590", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 23, "title": "Anticoagulation Safety - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK519025", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 24, "title": "Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9569921", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "[PDF] Cellular, Tissue, and Gene Therapies Advisory Committee ... - FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/183676/download", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "Committee Available for Public Disclosure Page 47 of 95 Table 11: ANNEXA-4 Adverse Event Overview (Safety Population) Adverse Event, n (%) Safety Population (N=477) Any adverse event 346 (72.5) AE leading to treatment discontinuation 4 (0.8) Serious adverse event 200 (41.9) AE leading to death withi", "score": 0.4224814 }, { "number": 2, "title": "[PDF] COUMADIN® TABLETS (Warfarin Sodium Tablets, USP) Crystalline ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "anticoagulation: a systematic review and meta-analysis. Lancet. 2006;367:404-411. Distributed by: Bristol-Myers Squibb Company Princeton, New Jersey 08543 USA COUMADIN® and the color and configuration of COUMADIN tablets are trademarks of Bristol-Myers Squibb Pharma Company. Copyright © Bristol-Myer", "score": 0.16410108 }, { "number": 3, "title": "Endoscopy in patients on antiplatelet or anticoagulant therapy - Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/gutjnl/70/9/1611.full.pdf", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "Restarting antithrombotic therapy for elective procedures There are few data to inform us on the optimal time to restart antithrombotic therapy, if discontinued, after elective endo-scopic therapy. Decisions in all cases will be based on the perceived risk of haemorrhage following the procedure vers", "score": 0.71113056 }, { "number": 4, "title": "Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018 | Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/67/10/1757", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "Once the bleeding is controlled, the decision to resume anticoagulants should be made by a multidisciplinary team with cardiologist, gastroenterologist, intensivist and, if feasible, with patient’s participation. The CHA2DS2-VASC and HAS-BLED score are useful in assessing the need for continuing ant", "score": 0.6688159 }, { "number": 5, "title": "Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines | Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/67/3/405", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "Since the risk of early rebleeding decreases considerably after the first 3 days and the time required for full re-anticoagulation may be prolonged, especially after warfarin reversal, we recommend early resumption of warfarin after day 3, especially in patients with high thromboembolic risk. Accord", "score": 0.6633424 }, { "number": 6, "title": "Management of patients on antithrombotic agents", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/gutjnl/67/3/405.full.pdf", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "Since the risk of early rebleeding decreases considerably after the first 3 days and the time required for full re-anticoagulation may be prolonged, especially after warfarin reversal, we recom-mend early resumption of warfarin after day 3, especially in patients with high thromboembolic risk. Accor", "score": 0.64773196 }, { "number": 7, "title": "Spontaneous rectal sheath bleed while on DOAC anticoagulation", "detail": "casereports.bmj.com", "url": "https://casereports.bmj.com/content/bmjcr/16/11/e254313.full.pdf", "authors": "casereports.bmj.com", "host": "casereports.bmj.com", "snippet": "Following resolution of the bleeding, the decision as to whether and when to restart anticoagulation can be challenging and is often complicated by the presence of extensive comorbid-ities, the degree of stroke risk, circumstances around the initial bleed and patient preference. Generally, it is rea", "score": 0.77137923 }, { "number": 8, "title": "Spontaneous rectal sheath bleed while on DOAC anticoagulation | BMJ Case Reports", "detail": "casereports.bmj.com", "url": "https://casereports.bmj.com/content/16/11/e254313", "authors": "casereports.bmj.com", "host": "casereports.bmj.com", "snippet": "Title: Spontaneous rectal sheath bleed while on DOAC anticoagulation | BMJ Case Reports\nHowever, as with all anticoagulant therapy, they have a not insignificant risk of bleeding, both provoked and spontaneous.3–5 While reversal agents such as idarucizumab and, more recentl,y andexanet alfa have bee", "score": 0.6437107 }, { "number": 9, "title": "Timing of anticoagulation restart after serious bleeding in atrial ...", "detail": "heart.bmj.com", "url": "https://heart.bmj.com/content/112/5/253", "authors": "heart.bmj.com", "host": "heart.bmj.com", "snippet": "of VKA after gastrointestinal bleeding and found that early restart of VKA was associated with a decreased risk of death and thromboembolism and was not associated with an increased risk of gastrointestinal bleeding compared with late restart. Whether all these findings also apply to the restart of ", "score": 0.6158511 }, { "number": 10, "title": "Timing of anticoagulation restart after serious bleeding in atrial fibrillation | Heart", "detail": "heart.bmj.com", "url": "https://heart.bmj.com/content/early/2025/07/16/heartjnl-2024-325343.responses", "authors": "heart.bmj.com", "host": "heart.bmj.com", "snippet": "Title: Timing of anticoagulation restart after serious bleeding in atrial fibrillation | Heart\nTiming of anticoagulation restart after serious bleeding in atrial fibrillation. * Correspondence on “Timing of anticoagulation restart after serious bleeding in atrial fibrillation” by Al-Hussainy et al. ", "score": 0.5335682 }, { "number": 11, "title": "Timing of anticoagulation restart after serious bleeding in atrial fibrillation", "detail": "heart.bmj.com", "url": "https://heart.bmj.com/content/early/2025/07/16/heartjnl-2024-325343.full", "authors": "heart.bmj.com", "host": "heart.bmj.com", "snippet": "Title: Timing of anticoagulation restart after serious bleeding in atrial fibrillation\n**Background** Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation (AF) presents a clinical dilemma, with limited evidence on the balance between strok", "score": 0.50944775 }, { "number": 12, "title": "Management of Nonvariceal Upper Gastrointestinal Bleeding", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M19-1795", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "Early versus delayed resumption of anticoagulation after endoscopic hemostasis in upper gastrointestinal bleeding: a propensity-score analysis.", "score": 0.4811862 }, { "number": 13, "title": "Risk of gastrointestinal rebleeding in direct oral anticoagulant-treated population | Postgraduate Medical Journal | Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/pmj/article/101/1202/1361/8196324", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "We performed a retrospective analysis of rebleeding events and their association with direct oral anticoagulant (DOAC) discontinuation versus resumption in patients admitted with an index episode of gastrointestinal bleeding (GIB) while on oral anticoagulants. Previous episode of GIB is the most sig", "score": 0.7187726 }, { "number": 14, "title": "HAS-BLED and CHA2DS2-VASc Scores as Predictors of Bleeding and Thrombotic Risk After Continuous-Flow Ventricular Assist Device Implantation - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1071916414011907", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### J Heart Lung Transplant\n\n### Incidence and management of gastrointestinal bleeding with continuous flow assist devices\n\n### Ann Thorac Surg\n\n### Gastrointestinal bleeding with the HeartMate II left ventricular assist device\n\n### J Heart Lung Transplant\n\n### Evaluation of GI bleeding after implan", "score": 0.533714 }, { "number": 15, "title": "Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0016510798700574", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures - ScienceDirect\nAnticoagulation therapy complicates the management of gastrointestinal bleeding. When preparing for an endoscopic procedure on an anticoagulated patient considerations include: (1", "score": 0.7625837 }, { "number": 16, "title": "Management of Anticoagulation-related Bleeding: A... : Iranian Journal of Cardiovascular Medicine", "detail": "journals.lww.com", "url": "https://journals.lww.com/rcvm/fulltext/2026/01000/management_of_anticoagulation_related_bleeding__a.2.aspx?context=latestarticles", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "bleeding events in ≤10% of patients. Based on their clinical experience, HCPs most frequently identified dabigatran and rivaroxaban as the DOACs commonly linked to gastrointestinal bleeding and menorrhagia. Switching to an alternative DOAC following a major bleeding event was reported to be uncommon", "score": 0.7125728 }, { "number": 17, "title": "Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/0002934388901052", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Moreover, we describe and discuss the clinical applications and optimal dosages of oral anticoagulant therapies, practical issues related to their initiation and monitoring, adverse events such as bleeding and other potential side effects, and available strategies for reversal. Among the key recomme", "score": 0.49348235 }, { "number": 18, "title": "Restarting Warfarin vs Direct Oral Anticoagulants After Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1542356520315639", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### Ann Intern Med\n\n## Cited by (22)\n\n### No Association between Gastrointestinal Rebleeding and DOAC Therapy Resumption: A Systematic Review and Meta-Analysis\n\n### Management of Patients With Acute Lower Gastrointestinal Bleeding: An Updated ACG Guideline\n\n### Re-starting anticoagulation and antipl", "score": 0.47913864 }, { "number": 19, "title": "associated gastrointestinal bleeding: Framework for decisions about ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15466", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol. 2014;113:662- 668. 47", "score": 0.735737 }, { "number": 20, "title": "Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation - Johner - 2026 - European Journal of Clinical Investigation - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/eci.70224", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "| High gastrointestinal bleeding risk | Proton pump inhibitor for patients with risk factors: – History of gastrointestinal bleeding – History of peptic ulcer – Gastro-oesophageal reflux disease – Helicobacter pylori infection – Cirrhosis – Dyspepsia – Advanced age – Excessive alcoh", "score": 0.6052631 }, { "number": 21, "title": "Recurrent bleeding and thrombotic events after resumption of oral ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/jth.15476", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Anticoagulant therapy was associated with lower thromboembolism and higher recurrent bleeding. ation for atrial fibrillation, VTE, or", "score": 0.55275756 }, { "number": 22, "title": "Perioperative Anticoagulation Management - StatPearls - NCBI - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK557590", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "It is important to note that bridging therapy is not indicated in patients on DOACs. The predictable pharmacological effect of DOACs allows a properly timed interruption of anticoagulation therapy before surgery. Various societies have issued recommendations about the timing of DOAC interruption. Ou", "score": 0.588062 }, { "number": 23, "title": "Anticoagulation Safety - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK519025", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "syndrome and stenting. Neurology and neurosurgery input is critical in anticoagulant-associated intracranial hemorrhage to guide reversal, neurosurgical interventions, and timing of anticoagulation resumption, while gastroenterology and interventional radiology should be engaged for significant gast", "score": 0.53050464 }, { "number": 24, "title": "Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9569921", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "### Resumption of Anticoagulation After GIB\n\nUp to 25–50% of patients still do not restart oral anticoagulation after GIB, although available evidence suggests that the benefits of resuming anticoagulation (decreased thromboembolic events and mortality) outweigh the risk of bleeding in patients with", "score": 0.8106142 } ], "publishedAt": "2026-09-15T17:48:02.871193+00:00", "updatedAt": "2026-09-15T17:48:02.871193+00:00", "readingMinutes": 7, "slug": "anticoagulation-after-gastrointestinal-bleeding" }